Home » Stocks » GILD

Gilead Sciences, Inc. (GILD)

Stock Price: $60.12 USD 0.09 (0.15%)
Updated November 30, 12:43 PM EST - Market open

Stock Price Chart

Key Info

Market Cap 75.36B
Revenue (ttm) 23.15B
Net Income (ttm) 1.27B
Shares Out 1.25B
EPS (ttm) 1.01
PE Ratio 59.52
Forward PE 8.79
Dividend $2.72
Dividend Yield 4.52%

Stock Quote

Trading Day November 30
Last Price $60.12
Previous Close $60.03
Change ($) 0.09
Change (%) 0.15%
Day's Open 59.77
Day's Range 59.64 - 60.25
Day's Volume 3,908,848
52-Week Range 58.15 - 82.40

More Stats

Market Cap 75.36B
Enterprise Value 80.68B
Earnings Date (est) n/a
Ex-Dividend Date Sep 14, 2020
Shares Outstanding 1.25B
Float n/a
EPS (basic) 0.98
EPS (diluted) 1.01
FCF / Share 6.50
Dividend $2.72
Dividend Yield 4.52%
Earnings Yield 1.68%
FCF Yield 10.83%
Payout Ratio 272.40%
Shares Short 21.71M
Short Ratio 2.06
Short % of Float n/a
Beta 0.55
PE Ratio 59.52
Forward PE 8.79
P/FCF Ratio 9.24
PS Ratio 3.26
PB Ratio 4.28
Revenue 23.15B
Operating Income 2.51B
Net Income 1.27B
Free Cash Flow 8.16B
Net Cash -5.32B
Net Cash / Share -4.24
Gross Margin 76.79%
Operating Margin 10.86%
Profit Margin 5.50%
FCF Margin 35.25%
ROA 5.15%
ROE 6.46%
ROIC 5.80%
Stats based on trailing-twelve-month (ttm) numbers.

Analyst Forecasts

Analyst Ratings (30)

Buy 11
Overweight 1
Hold 16
Underweight 0
Sell 2

Analyst Consensus: Overweight

Price Target

$73.46*
(22.19% upside)
Low
58.0
Current: $60.12
High
105.0
Target: 73.46
*Average 12-month price target from 24 stock analysts.

Financial Performance

Financial numbers in millions USD.

Financial Overview

Year2019201820172016201520142013201220112010
Revenue22,44922,12726,10730,39032,63924,89011,2029,7028,3857,949
Revenue Growth1.46%-15.24%-14.09%-6.89%31.13%122.19%15.46%15.7%5.48%-
Gross Profit17,77417,27421,73626,12928,63321,1028,3437,2316,2616,080
Operating Income4,2878,20014,12417,63322,19315,2654,5244,0103,7903,962
Net Income5,3865,4554,62813,50118,10812,1013,0752,5922,8042,901
Shares Outstanding1,2701,2981,3071,3391,4641,5221,5291,5151,5501,712
Earnings Per Share4.224.173.519.9411.917.351.811.641.771.66
EPS Growth1.2%18.8%-64.69%-16.54%62.04%306.08%10.37%-7.34%6.63%-
Dividend Per Share2.522.282.081.841.29-----
Dividend Growth10.53%9.62%13.04%42.64%------
Operating Cash Flow9,1448,40011,89817,04721,25012,8183,1053,1953,6392,834
Capital Expenditures-825-924-590-748-747-557-190-397-132-61.88
Free Cash Flow8,3197,47611,30816,29920,50312,2612,9152,7983,5072,772
Cash & Equivalents24,35230,08925,51011,89514,60710,1282,1321,8629,9002,099
Total Debt24,59327,32233,54226,34622,05512,4046,6368,2247,6073,485
Net Cash / Debt-2412,767-8,032-14,451-7,448-2,276-4,504-6,3622,293-1,386
Assets61,62763,67570,28356,97751,71634,66422,57921,24017,30311,593
Liabilities38,97742,14149,78237,61432,60318,84510,83411,69610,4365,471
Book Value22,52521,38720,44218,88718,53415,42611,3709,3036,7395,864
Numbers in millions USD, except per-share numbers.

Company Profile

Company Details

Full Name Gilead Sciences, Inc.
Country United States
Employees 11,800
CEO Daniel P. O'Day

Stock Information

Ticker Symbol GILD
Stock Exchange NASDAQ
Sector Healthcare
Industry Drug Manufacturers—General
Unique Identifier NASDAQ: GILD
IPO Date January 22, 1992

Description

Gilead Sciences, a research-based biopharmaceutical company, discovers, develops, and commercializes medicines in the areas of unmet medical needs in the United States, Europe, and internationally. The company's products include Biktarvy, Descovy, Odefsey, Genvoya, Stribild, Complera/Eviplera, Atripla, and Truvada for the treatment of human immunodeficiency virus (HIV) infection; and Vosevi, Vemlidy, Epclusa, Harvoni, and Viread products for treating liver diseases. It also provides Yescarta, a chimeric antigen receptor T cell therapy for adult patients with relapsed or refractory large B-cell lymphoma; Zydelig, a kinase inhibitor; Letairis, an oral formulation of an endothelin receptor antagonist for pulmonary arterial hypertension; Ranexa, a tablet to treat chronic angina; and AmBisome, an antifungal agent to treat serious invasive fungal infections. In addition, the company offers its products under the name Cayston, Emtriva, Hepsera, Sovaldi, and Tybost. Further, it develops product candidates for the treatment of viral diseases, inflammatory and fibrotic diseases, and oncology. The company markets its products through its commercial teams; and in conjunction with third-party distributors and corporate partners. Gilead Sciences, Inc. has collaboration agreements with Bristol-Myers Squibb Company; Janssen Sciences Ireland UC; Japan Tobacco Inc.; Galapagos NV; Second Genome; Gadeta; Carna Biosciences Inc.; Nurix Therapeutics, Inc.; Humanigen, Inc.; Kiniksa Pharmaceuticals, Ltd.; Kyverna Therapeutics, Inc.; Glympse Bio, Inc.; Renown Institute for Health Innovation; Goldfinch Bio, Inc.; Insitro, Inc.; Novo Nordisk A/S; Yuhan Corporation; Kite Pharma, Inc.; oNKo-innate Pty. Ltd.; and Roche Holding AG. The company has partnership with Arcus Biosciences, Inc. to co-develop and co-commercialize next-generation cancer immunotherapies. Gilead Sciences, Inc. was founded in 1987 and is headquartered in Foster City, California.